Premium
Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1‐year treat‐to‐target trial
Author(s) -
Davies M.,
Sasaki T.,
Gross J. L.,
Bantwal G.,
Ono Y.,
Nishida T.,
Tojjar D.,
Seino H.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12573
Subject(s) - insulin degludec , insulin detemir , medicine , tolerability , type 2 diabetes , insulin glargine , randomized controlled trial , insulin , endocrinology , diabetes mellitus , hypoglycemia , adverse effect
The long‐term safety and tolerability of insulin degludec ( IDeg ) was compared with that of insulin detemir ( IDet ), as basal treatment in participants with type 1 diabetes mellitus ( T1DM ). In the present multinational, 26‐week core + 26‐week extension, controlled, open‐label, parallel‐group trial, adults with T1DM were randomized to IDeg or IDet as basal insulin treatment combined with meal‐time bolus insulin aspart. IDeg was administered once daily, whilst IDet was administered once or twice daily depending on patients' glycaemic control. After 1 year, IDeg provided a 33% lower rate of nocturnal hypoglycaemia compared with IDet : estimated rate ratio ( IDeg : IDet ) 0.67 [95% confidence interval ( CI ) 0.51; 0.88]; p < 0.05. IDeg improved glycated haemoglobin after 1 year of treatment, similarly to IDet , but IDeg also provided a significantly greater reduction in fasting plasma glucose compared with IDet : estimated difference ( IDeg − IDet ) −1.11 (95% CI −1.83; −0.40) mmol/l; p < 0.05. The present study confirmed the long‐term safety and tolerability profile of IDeg in patients with T1DM . IDeg provided a lower risk of nocturnal confirmed hypoglycaemia than IDet .